A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-10
DOI
10.3389/fimmu.2019.01593
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation
- (2019) Josée Golay et al. BLOOD
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells
- (2018) Jens H.W. Pahl et al. Cancer Immunology Research
- Amatuximab and novel agents targeting mesothelin for solid tumors
- (2017) Paolo Baldo et al. OncoTargets and Therapy
- The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis
- (2017) Hai Li et al. Oncology Letters
- Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
- (2017) Neelima Vidula et al. Oncotarget
- MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ
- (2016) David Legland et al. BIOINFORMATICS
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- (2016) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer
- (2016) Emmanuel Zervos et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
- (2016) Wei Hseun Yeap et al. Scientific Reports
- Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers
- (2015) Ibrahim Vedat Bayoglu et al. BIOMEDICINE & PHARMACOTHERAPY
- Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
- (2015) Julia Stieglmaier et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications
- (2015) Andrew M. Prantner et al. Journal of Biomedical Nanotechnology
- A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
- (2015) Marc Turini et al. Oncotarget
- Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer
- (2015) Christine Mehner et al. Oncotarget
- Mesothelin expression is associated with poor outcomes in breast cancer
- (2014) Yun R. Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status
- (2014) Stefanie Raab et al. JOURNAL OF IMMUNOLOGY
- Efficient Bayesian-based multiview deconvolution
- (2014) Stephan Preibisch et al. NATURE METHODS
- Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
- (2014) Gary Tozbikian et al. PLoS One
- The Role of Mesothelin in Tumor Progression and Targeted Therapy
- (2013) Zhewei Tang et al. Anti-Cancer Agents in Medicinal Chemistry
- High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy
- (2013) Francesco Pampaloni et al. CELL AND TISSUE RESEARCH
- Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
- (2013) C. Rozan et al. MOLECULAR CANCER THERAPEUTICS
- Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
- (2013) Shih-Hsun Chen et al. Scientific Reports
- Mesothelin, a novel immunotherapy target for triple negative breast cancer
- (2012) Julia Tchou et al. BREAST CANCER RESEARCH AND TREATMENT
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
- (2012) E. L. Servais et al. CLINICAL CANCER RESEARCH
- Dynamics of NK cell interactionsin vivo
- (2012) Jacques Deguine et al. IMMUNOLOGICAL REVIEWS
- Preparation strategy and illumination of three-dimensional cell cultures in light sheet–based fluorescence microscopy
- (2012) Thomas Bruns et al. JOURNAL OF BIOMEDICAL OPTICS
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
- (2012) R. J. Kelly et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
- (2012) Kun Wang et al. PLoS One
- Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action
- (2010) Franziska Hirschhaeuser et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter
- (2010) Ke Tan et al. HUMAN PATHOLOGY
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of human NK-cell cytokine and chemokine production by target cell recognition
- (2009) C. Fauriat et al. BLOOD
- Spheroid-based drug screen: considerations and practical approach
- (2009) Juergen Friedrich et al. Nature Protocols
- Therapeutic Strategies for Triple-Negative Breast Cancer
- (2008) Antoinette R. Tan et al. CANCER JOURNAL
- Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
- (2008) Carole Sapede et al. CANCER SCIENCE
- Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells
- (2008) N. Uehara et al. MOLECULAR CANCER RESEARCH
- Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
- (2008) L. J. Holt et al. PROTEIN ENGINEERING DESIGN & SELECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search